Among the studies of biologic treatments or cytokine inhibitors in COPD where smoking status significantly impacted drug efficacy, most therapies seem to benefit active smokers more than ex-smokers, with the exception of the anti-IL-33 mAb, itepekimab (Table 1) (Rabe et al., 2021). The gene discussed is IL33; the disease is chronic obstructive pulmonary disease.